论文部分内容阅读
目的探索分析针对急性冠状动脉综合征(ACS)急性期患者应用不同剂量瑞舒伐他汀治疗对其脂蛋白相关磷脂酶A2(Lp-PLA_2)以及超敏C反应蛋白(hs-CRP)的作用和影响。方法 120例ACS患者作为研究对象,随机分为常规剂量组与大剂量组,每组60例。两组患者均接受相关针对性治疗,常规剂量组加用常规剂量(20 mg/d)瑞舒伐他汀治疗,大剂量组加用大剂量(40 mg/d)瑞舒伐他汀治疗。分别于治疗前及治疗10 d后测量患者的血浆Lp-PLA_2及hs-CRP水平,并进行组间比较。结果治疗前两组血浆炎症因子Lp-PLA_2、hs-CRP水平比较差异均无统计学意义(P>0.05)。治疗10 d后,两组血浆Lp-PLA_2、hs-CRP水平均较治疗前明显下降,且大剂量组Lp-PLA_2、hs-CRP水平(22.59±3.49)μmol/L、(6.62±2.19)mg/L均低于常规剂量组(29.23±4.30)μmol/L、(9.05±2.91)mg/L,差异均具有统计学意义(P<0.05)。结论瑞舒伐他汀可以有效降低ACS患者的Lp-PLA_2、hs-CRP水平,较大剂量(40 mg/d)较常规剂量(20 mg/d)可以实现更好的效果,具有极大的推广应用价值。
Objective To investigate the effects of different doses of rosuvastatin on the expression of Lp-PLA_2 and hs-CRP in patients with acute coronary syndrome (ACS) at acute stage. influences. Methods A total of 120 ACS patients were randomly divided into routine dose group and high dose group, 60 cases in each group. Patients in both groups received relevant targeted therapy. Patients in the conventional dose group received rosuvastatin at a normal dose (20 mg / d) and rosuvastatin at a high dose (40 mg / d) in the high dose group. The levels of plasma Lp-PLA_2 and hs-CRP were measured before treatment and after 10 days of treatment, respectively, and compared between groups. Results There were no significant differences in the levels of plasma inflammatory cytokines Lp-PLA_2 and hs-CRP between the two groups before treatment (P> 0.05). After 10 days of treatment, the levels of Lp-PLA_2 and hs-CRP in both groups were significantly lower than those before treatment, and the levels of Lp-PLA_2 and hs-CRP in the high-dose group were (22.59 ± 3.49) μmol / L, (6.62 ± 2.19) mg / L were lower than the conventional dose group (29.23 ± 4.30) μmol / L, (9.05 ± 2.91) mg / L, the difference was statistically significant (P <0.05). Conclusion Rosuvastatin can effectively reduce the levels of Lp-PLA_2 and hs-CRP in patients with ACS. The higher dose (40 mg / d) can achieve better results than the conventional dose (20 mg / d), which is of great promotion Value.